vs

Side-by-side financial comparison of Alpha Metallurgical Resources, Inc. (AMR) and Ascendis Pharma A/S (ASND). Click either name above to swap in a different company.

Alpha Metallurgical Resources, Inc. is the larger business by last-quarter revenue ($519.1M vs $267.3M, roughly 1.9× Ascendis Pharma A/S). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs -15.7%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs -22.4%).

Alpha Metallurgical Resources, formerly Contura Energy, is a leading coal supplier with underground and surface coal mining complexes across Northern and Central Appalachia. Contura owns large coal basins in Pennsylvania, Virginia and West Virginia which supply both metallurgical coal to produce steel and thermal coal to generate power.

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

AMR vs ASND — Head-to-Head

Bigger by revenue
AMR
AMR
1.9× larger
AMR
$519.1M
$267.3M
ASND
Growing faster (revenue YoY)
ASND
ASND
+58.0% gap
ASND
42.3%
-15.7%
AMR
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
-22.4%
AMR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AMR
AMR
ASND
ASND
Revenue
$519.1M
$267.3M
Net Profit
$-17.3M
Gross Margin
90.5%
Operating Margin
-4.1%
Net Margin
-3.3%
Revenue YoY
-15.7%
42.3%
Net Profit YoY
-711.2%
EPS (diluted)
$-1.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMR
AMR
ASND
ASND
Q4 25
$519.1M
$267.3M
Q3 25
$525.2M
$230.7M
Q2 25
$548.7M
$170.7M
Q1 25
$529.7M
$109.0M
Q4 24
$615.4M
$187.8M
Q3 24
$669.8M
$62.5M
Q2 24
$800.1M
$38.9M
Q1 24
$861.3M
$103.6M
Net Profit
AMR
AMR
ASND
ASND
Q4 25
$-17.3M
Q3 25
$-5.5M
$-65.9M
Q2 25
$-5.0M
$-42.0M
Q1 25
$-33.9M
$-102.2M
Q4 24
$-2.1M
Q3 24
$3.8M
$-107.1M
Q2 24
$58.9M
$-118.1M
Q1 24
$127.0M
$-141.5M
Gross Margin
AMR
AMR
ASND
ASND
Q4 25
90.5%
Q3 25
89.5%
Q2 25
80.1%
Q1 25
82.6%
Q4 24
91.9%
Q3 24
80.6%
Q2 24
68.2%
Q1 24
92.1%
Operating Margin
AMR
AMR
ASND
ASND
Q4 25
-4.1%
Q3 25
-0.5%
5.1%
Q2 25
0.5%
-33.5%
Q1 25
-7.6%
-103.2%
Q4 24
1.6%
Q3 24
0.8%
-167.3%
Q2 24
8.8%
-370.2%
Q1 24
16.5%
-51.2%
Net Margin
AMR
AMR
ASND
ASND
Q4 25
-3.3%
Q3 25
-1.1%
-28.5%
Q2 25
-0.9%
-24.6%
Q1 25
-6.4%
-93.7%
Q4 24
-0.3%
Q3 24
0.6%
-171.5%
Q2 24
7.4%
-303.9%
Q1 24
14.7%
-136.6%
EPS (diluted)
AMR
AMR
ASND
ASND
Q4 25
$-1.35
Q3 25
$-0.42
Q2 25
$-0.38
Q1 25
$-2.60
Q4 24
$-0.09
Q3 24
$0.29
Q2 24
$4.49
Q1 24
$9.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMR
AMR
ASND
ASND
Cash + ST InvestmentsLiquidity on hand
$415.6M
$665.3M
Total DebtLower is stronger
$9.8M
Stockholders' EquityBook value
$1.5B
$-175.8M
Total Assets
$2.3B
$1.4B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMR
AMR
ASND
ASND
Q4 25
$415.6M
$665.3M
Q3 25
$457.9M
$582.2M
Q2 25
$449.0M
$533.6M
Q1 25
$448.0M
$559.4M
Q4 24
$481.6M
$604.3M
Q3 24
$484.6M
$675.6M
Q2 24
$336.1M
$279.4M
Q1 24
$269.4M
$345.9M
Total Debt
AMR
AMR
ASND
ASND
Q4 25
$9.8M
Q3 25
$2.9M
Q2 25
$3.1M
Q1 25
$2.4M
Q4 24
$2.9M
Q3 24
$3.6M
Q2 24
$5.3M
Q1 24
$6.0M
Stockholders' Equity
AMR
AMR
ASND
ASND
Q4 25
$1.5B
$-175.8M
Q3 25
$1.6B
$-188.0M
Q2 25
$1.6B
$-202.6M
Q1 25
$1.6B
$-205.0M
Q4 24
$1.6B
$-114.2M
Q3 24
$1.7B
$-105.1M
Q2 24
$1.6B
$-346.8M
Q1 24
$1.6B
$-257.2M
Total Assets
AMR
AMR
ASND
ASND
Q4 25
$2.3B
$1.4B
Q3 25
$2.3B
$1.2B
Q2 25
$2.4B
$1.2B
Q1 25
$2.4B
$1.1B
Q4 24
$2.4B
$1.3B
Q3 24
$2.5B
$1.2B
Q2 24
$2.5B
$819.0M
Q1 24
$2.5B
$866.7M
Debt / Equity
AMR
AMR
ASND
ASND
Q4 25
0.01×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMR
AMR
ASND
ASND
Operating Cash FlowLast quarter
$19.0M
$58.2M
Free Cash FlowOCF − Capex
$-10.0M
FCF MarginFCF / Revenue
-1.9%
Capex IntensityCapex / Revenue
5.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$17.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMR
AMR
ASND
ASND
Q4 25
$19.0M
$58.2M
Q3 25
$50.5M
Q2 25
$53.2M
Q1 25
$22.2M
$-15.5M
Q4 24
$56.3M
$-330.7M
Q3 24
$189.5M
Q2 24
$138.1M
Q1 24
$196.1M
$-109.7M
Free Cash Flow
AMR
AMR
ASND
ASND
Q4 25
$-10.0M
Q3 25
$25.4M
Q2 25
$18.6M
Q1 25
$-16.3M
Q4 24
$13.6M
Q3 24
$158.0M
Q2 24
$77.0M
Q1 24
$132.5M
FCF Margin
AMR
AMR
ASND
ASND
Q4 25
-1.9%
Q3 25
4.8%
Q2 25
3.4%
Q1 25
-3.1%
Q4 24
2.2%
Q3 24
23.6%
Q2 24
9.6%
Q1 24
15.4%
Capex Intensity
AMR
AMR
ASND
ASND
Q4 25
5.6%
Q3 25
4.8%
Q2 25
6.3%
Q1 25
7.3%
Q4 24
6.9%
Q3 24
4.7%
Q2 24
7.6%
Q1 24
7.4%
Cash Conversion
AMR
AMR
ASND
ASND
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
49.81×
Q2 24
2.34×
Q1 24
1.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons